Long-term administration of the mitochondria-targeted antioxidant mitoquinone mesylate fails to attenuate age-related oxidative damage or rescue the loss of muscle mass and function associated with aging of skeletal muscle. by Sakellariou, GK et al.
1 
 
FASEB Journal 
 
Version R1  
 
Research Communication article 
 
 
Long-term administration of the mitochondria-targeted antioxidant mitoquinone mesylate fails to attenuate age-
related oxidative damage or rescue the loss of muscle mass and function associated with aging of skeletal muscle 
 
 
Giorgos K Sakellariou1,2, Timothy Pearson1, Adam P Lightfoot1, Gareth A Nye1, Nicola Wells1, Ifigeneia I. 
Giakoumaki1, Richard D Griffiths1, Anne McArdle1 and Malcolm J Jackson1*. 
 
 
Affiliations 
1MRC-Arthritis Research UK Centre for Integrated Research into Musculoskeletal Ageing, Department of 
Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, 
L693GA, U.K.  
 
2Current address: GeneFirst Ltd, Culham Science Centre, Abingdon, Oxfordshire, OX14 3DB, UK. 
 
 
Running title: Mitoquinone mesylate fails to prevent sarcopenia and age-related oxidative damage 
 
 
*Corresponding author:  
Prof. M. J. Jackson,      
Institute of Ageing and Chronic Disease    
University of Liverpool,      
Liverpool, L693GA, U.K.       
Tel: (44)1517064072,        
Fax: (44)151706580,       
E-mail: mjj@liverpool.ac.uk 
2 
 
List of Abbreviations 
 
3-NT, 3-Nitrotyrosine; 4-HNE, 4-hydroxynonenal; 8-OHdG, 8-hydroxydeoxyguanosine; AT, anterior tibialis; 
EDL, extensor digitorum longus; GTN, gastrocnemius; SOL, soleus muscle; B2M, beta-2 microglobulin;  BW, 
body weight CAT, catalase;  COX I, cytochrome c oxidase subunit I; COX IV, cytochrome c oxidase subunit 
IV; CS, citrate synthase; CSA, cross-sectional area; DRP1, dynamin related protein-1; FIS1, mitochondrial 
fission-1 protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; gDNA, genomic DNA; GPX1, 
glutathione peroxidase 1; H2O2, hydrogen peroxide; HSP, heat shock protein; MCIP1, modulatory calcineurin 
interacting protein-1; MFN1, mitofusin-1; MFN2, mitofusin-2; Mitoquinone mesylate (MitoQ), [10-(4,5-
dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl] triphenylphosphonium;  mtDNA, mitochondrial 
DNA; mtROS, mitochondrial ROS; ND1, mitochondrial encoded NADH dehydrogenase-1; nuclear factor 
kappa B, NFκB; NOS, nitric oxide synthase isoenzymes; NOX4, nicotinamide adenine dinucleotide phosphate 
oxidase 4; NRF1, nuclear respiratory factor-1; OGG1, oxoguanine DNA glycosylase; OPA1, optic atrophy 
type-1; PBS, Phosphate Buffered Saline; PECAM 1, platelet endothelial cell adhesion molecule-1; PGC1α, 
peroxisome proliferator-activated receptor α; PINK1, PTEN-induced putative kinase 1; Poly-UB, polyubiquitin; 
PRXV, peroxiredoxin V; RCI, respiratory control index; RONS, reactive oxygen and nitrogen species; RPS29, 
ribosomal protein S29; SOD, superoxide dismutase;  TFAM, mitochondrial transcription factor A; TMRM, 
tetramethylrhodamine, methyl ester fluorescence; TRX, thioredoxin; TRXR, thioredoxin reductase; TPP+, 
triphenylphosphonium; UCP, uncoupling protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Abstract 
 
Age-related skeletal muscle dysfunction is the underlying cause of morbidity that affects up to half the 
population aged 80 or over. Considerable evidence indicates that oxidative damage and mitochondrial 
dysfunction contribute to the sarcopenic phenotype that occurs with aging. To examine this, we administered 
the mitochondria-targeted antioxidant mitoquinone mesylate (also known as MitoQ, 100μM) to wild-type 
C57BL/6 mice for 15 weeks (from 24 to 28 mo of age) and investigated the effects on age-related loss of 
muscle mass and function, changes in redox homeostasis and mitochondrial organelle integrity and function. 
Here we show that mitoquinone mesylate treatment failed to prevent age-dependent loss of skeletal muscle 
mass associated with myofiber atrophy or alter a variety of in situ and ex vivo muscle function analyses 
including maximum isometric tetanic force, decline in force following a tetanic fatiguing protocol and single 
fiber specific force. Furthermore, we provide evidence that long-term mitoquinone mesylate administration did 
not reduce mitochondrial reactive oxygen species nor induce significant changes in muscle redox homeostasis, 
assessed by changes in 4-hydroxynonenal protein adducts, protein carbonyl content, protein nitration and DNA 
damage determined by the content of 8-hydroxydeoxyguanosine. Mitochondrial membrane potential, abundance 
and respiration assessed in permeabilized myofibers was not significantly altered in response to mitoquinone 
mesylate treatment. Collectively, these findings demonstrate that long-term mitochondria-targeted mitoquinone 
mesylate administration failed to attenuate age-related oxidative damage in skeletal muscle of old mice or 
provide any protective effect in the context of muscle aging. 
 
Key words: superoxide, SOD, heat shock proteins, NOX4, NFκB.  
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Introduction  
Age-related loss of muscle mass and function underlies morbidity and mortality that affects up to half the 
population aged 80 or older (1). Loss of muscle strength in the elderly is a contributor to loss of independence, 
and physical disability, which is linked with increased risk of falls and fractures. Many structural and functional 
changes occur with advancing age in skeletal muscle including a reduction in the number and cross-sectional 
area (CSA) of individual muscle fibers (2).  
 
Oxidative stress has been suggested to be among the factors contributing to the initiation and progression of 
sarcopenia that occurs during aging (3, 4). Reports from our group (5-11) and others (12, 13) have shown that 
genetic manipulations of redox regulatory systems modifies the muscle aging process. Skeletal muscle has a  
high content of mitochondria (14) and mitochondrial redox homeostasis has been proposed to play a key role in 
age-related oxidative damage (15). Consistent with a role of mitochondria as a contributor to age-related muscle 
redox changes, studies have shown that isolated skeletal muscle mitochondria exhibit an age-dependent increase 
in hydrogen peroxide (H2O2) generation (16, 17).  
 
Reactive oxygen species (ROS) derived from mitochondria (mtROS) are linked to the pathogenesis of a number 
of age-related human diseases including neurodegenerative disorders, ischemia-reperfusion injury and diabetes 
(18, 19). Considerable evidence has shown that mitochondrial oxidative damage can alter mitochondrial 
integrity and function in aging skeletal muscle including a reduction in mitochondrial abundance (20) and 
oxidative-phosphorylation (21), accumulation of mutated mtDNA (15) associated with impaired mitophagy 
(22), and increased mitochondrial-mediated apoptosis (23) which could all contribute to sarcopenia. Although 
cumulative oxidative damage has been suggested to induce age-associated decline in mitochondrial function 
(24), the effects of mitochondrial dysfunction and mtROS in age-related muscle atrophy remains a controversial 
topic (25, 26).  
 
To directly examine whether age-related atrophy and mitochondrial dysfunction is related to mitochondrial 
redox changes, we administered the mitochondria-targeted antioxidant mitoquinone mesylate (also known as 
MitoQ): [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl] triphenylphosphonium to 24 
mo old mice for 15 weeks and investigated the effects on age-related loss of muscle mass and function, changes 
in muscle redox homeostasis, mitochondrial organelle function and content. We hypothesized that if alterations 
in the mitochondrial redox status are implicated in the processes of age-related muscle wasting, mitoquinone 
mesylate drug treatment would ameliorate the sarcopenic phenotype associated with loss of muscle mass and 
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weakness. In the present study we report the effects of long-term administration of mitoquinone mesylate on 
muscle mass, morphology and function, redox homeostasis, adaptive responses and mitochondrial integrity and 
function in aging skeletal muscle. 
 
 
Materials and Methods 
Chemicals and Reagents. Unless stated otherwise, all chemicals used in this study were obtained from the 
Sigma Chemical Company. 
 
Mice. Male and female WT C57Bl/6 mice (8 mo old) were obtained from Charles River Laboratories (Margate, 
UK) and aged to 28 mo at the Biomedical Services Unit, University of Liverpool. All experiments were 
conducted in accordance with UK Home Office guidelines under the UK Animals (Scientific Procedures) Act 
1986. Mice were fed a CRM (P) rodent diet and were maintained under barrier conditions in microisolator cages 
on a 12-h dark/light cycle. For simple tissue collection, mice were euthanized by cervical dislocation, and 
muscles/tissues were either rapidly removed, snap-frozen, and stored at -80°C, or embedded in Tissue-Tek 
(VWR) and rapidly frozen in nitrogen-chilled isopentane for histological analysis. Mice subjected to in situ 
muscle force measurements were anesthetized with intraperitoneal (IP) injections of ketamine hydrochloride (66 
mg/kg) and medatomidine hydrochloride (0.55 mg/kg), with supplemental injections provided to maintain an 
adequate level of anaesthesia throughout the procedure. All procedures were approved by the University of 
Liverpool Animal Welfare and Ethical Review Body. 
 
Mitoquinone mesylate administration. Mice were 24 mo of age at the start of the treatment and were 
administered 100μM mitoquinone mesylate (as a β-cyclodextrin complex, supplied by Suzhou Vosun Chemical, 
China) in their drinking water for the subsequent 15 weeks. Fresh mitoquinone mesylate solutions were given 
twice a week, control mice were supplied with water without the supplement (n=8 mice/group). All mice were 
monitored daily and weighed once a week. We selectively chose to administer mice with mitoquinone mesylate 
between the age of 24 to 28 mo old since preliminary studies (Fig. 1A) showed that age-related muscle atrophy 
became apparent over the time period of 24-28 mo. The dosage of mitoquinone mesylate used in the present 
study was based on that previously used (100μM) to protect against oxidative damage in a mouse model of 
Alzheimer’s disease (27). Other previous studies have used mitoquinone mesylate doses as high as 500μM for 
up to 28 weeks (28). 
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In situ muscle function analysis. Extensor digitorum longus (EDL) muscle contractile properties were 
measured in situ as previously described (5). To assess the maximum isometric tetanic force (Po) of the EDL 
muscle, the distal tendon from anesthetized mice was severed and secured to the lever arm of a servomotor 
(Aurora Scientific). The knee of the hindlimb was fixed, the peroneal nerve was exposed, and bipolar platinum 
wire electrodes were placed across the nerve. Muscle optimal length (Lo) was determined using a series of 1 Hz 
stimulation and set at the length that generates the maximal force. For determination of Po, EDL muscles were 
electrically stimulated to contract at Lo and optimal stimulation voltage (8–10 V) at 2min intervals for 300ms 
with 0.2ms pulse width. Po was assessed by increasing the frequency of stimulation from 10 to 50 Hz and, 
subsequently, in 50-Hz increments to a maximum of 300Hz. Po was identified when the maximum force 
reached a plateau, despite increasing stimulation frequency. After identification of Po, mice were subjected to a 
repetitive tetanic fatiguing protocol, which consisted of 60 consecutive isometric contractions (300ms at 100Hz 
every 5sec for 5min) (29). Following completion of the procedures, mice were killed by cervical dislocation, 
and muscles/tissues were rapidly removed. Muscle fiber length (Lf) and weight of EDL muscles were measured 
ex vivo to determine muscle cross-sectional area (CSA). Specific Po (mN/mm2) was calculated by dividing Po by 
total fiber CSA for each muscle.  
 
Determination of muscle structure. Anterior tibialis (AT) muscles were cryosectioned at -20°C through the 
mid-belly with a thickness of 12µm, and fluorescent immunohistochemical (IHC) staining was undertaken on 
the same day. Sections were rinsed with Phosphate Buffered Saline (PBS) and permeabilized in 0.2% Triton X-
100 in PBS for 5min. Fluorescein labelled wheat germ agglutinin (Vector Laboratories, 5µg/ml) was used to 
identify extracellular matrix. Nuclei were identified using 4’,6-diamidino-2-phenylindole (DAPI, 1µg/ml). 
Cross sections from 5-6 muscles/treatment group were examined by blinded observers to count the total number 
of fibers, percentage of centronucleated fibers and individual fiber CSA. To ensure that all fibers/section were 
analysed, consecutive images acquired from each cryosection at 10x magnification were merged into a single 
high-resolution image using Adobe photoshop CS5 (see Fig. 1B). Image J software was used to quantify 
individual fiber CSA.  
 
Confocal laser scanning microscopy. Fluorescence images were obtained using a C1 confocal laser scanning 
microscope (Nikon) equipped with a 405nm excitation diode laser, a 488nm excitation argon laser, and a 543nm 
excitation helium-neon laser. Emission fluorescence was detected through a set of 450/35, 515/30, and 605/15 
emission filters. Fluorescence images were analyzed with the EZC1 V.3.9 (12bit) acquisition software.  
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Preparation of permeabilized muscle fiber bundles. Selective plasma membrane permeabilization of fiber 
bundles was performed according to methods described by Kuznetsov et al (30) to allow analysis of intact 
skeletal muscle mitochondria in situ (19, 31). In brief, AT muscles were placed in ice-cold buffer A, containing 
(in mM) 50 K-MES, 7.23 K2EGTA, 2.77 CaK2EGTA, 20 imidazole, 0.5 DTT, 20 taurine, 5.3 Na2ATP, 15 PCr, 
and 6.56 MgCl2-6H2O (pH 7.3 at 4°C) and trimmed of connective tissue and fat. Muscles were manually teased 
into small bundles of fibers and treated with 50μg/ml saponin (in buffer A) for 30min at low rocking speed. 
Following permeabilization, fiber bundles prepared for mitochondrial H2O2 emission measurements, were 
washed 3x10min in ice-cold buffer Z, containing (in mM) 110 K-MES, 35 KCl, 1 EGTA, 5.3 Na2ATP, 10 
K2HPO4, and 3 MgCl2-6H2O (pH 7.3 at 4°C), supplemented with 5mg/ml BSA. Permeabilized fiber bundles 
prepared for respiration analyses were washed 3x10min in ice-cold buffer B containing, (in mM) 100 K-MES, 
7.23 K2EGTA, 2.77 CaK2EGTA, 20 imidazole, 0.5 DTT, 20 taurine, 3 K2HPO4, and 1.38 MgCl2-6H2O (pH 7.3 
at 4°C), supplemented with 2mg/ml BSA.  
 
Ex vivo single muscle fiber analysis. Isolated intact single muscle fibers were excised from the AT muscle and 
maintained in ice-cold relax solution, containing (in mM) 4.5 MgATP, 1 free Mg2+, 10 imidazole, 2 EGTA, and 
100 KCL (pH 7.0) (32). Single fibers were permeabilized with 50μg/ml saponin (in relax solution) for 15min on 
ice. Permeabilized fibers were mounted on an 802D muscle testing apparatus (Aurora Scientific), mounted upon 
insect pins with fine thread, attached to a 403A (5mN) force transducer and 312C length controller (see Fig. 
8H). Single fibers were maximally activated (pCa 4.5) ([-log[free Ca2+]) containing: (in mM) 5.3 MgATP, 1 
free Mg2+, 20 imidazole, 7 EGTA, 19.6 PCr, and 64 KCl (pH 7.0). Maximal force was recorded for each fiber 
and normalized to CSA (32). Sarcomere length for each individual myofiber was adjusted to 2.4-2.6μm and 
diameter measured at four intervals along the length of the fiber, and circular circumference assumed for the 
calculation of CSA.  
 
Mitochondrial respiration analysis. Permeabilized myofiber respiration was assessed using a Clark-type 
electrode in a continuously stirred sealed and thermostatically controlled chamber (Oxytherm System, 
Hansatech Instruments Ltd.) maintained at 37°C. Following calibration of the respiration chamber, 
permeabilized bundles (~15mg wet weight) were incubated in respiration buffer B (22, 31). Respiration (O2 
consumption) was determined using glutamate (5mM) and malate (5mM) substrates (G/M). ADP-stimulated 
respiration (state 3) was initiated by addition of ADP (0.3mM). Respiratory control index (RCI) was calculated 
by dividing state 3 by state 4 respiration and the efficiency of oxidative phosphorylation was determined by 
calculating the ratio of ATP amount to consumed O2 during state 3 respiration (P:O ratio).  
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Mitochondrial H2O2 emission measurements. Mitochondrial H2O2 efflux was measured using the Amplex 
Red-horseradish peroxidase (HRP, Molecular Probes) assay as previously described (16). H2O2 production was 
expressed as picomoles per minute per unit of Citrate Synthase (CS) activity. 
 
Mitochondrial DNA quantification. Mitochondrial DNA (mtDNA) was measured by quantitative RT-PCR 
(qRT-PCR) as described by Chen et al (33).  
 
DNA damage and DNA fragmentation. DNA damage was assessed by the content of 8-
hydroxydeoxyguanosine (8-OHdG) as described recently by Changou et al (34). Apoptotic DNA fragmentation 
was assessed by DNA laddering using agarose gel electrophoresis as described by Houot et al (35). 
 
Fluorescence-based methods to measure mitochondrial membrane potential and MitoSOX Red 
oxidation. To monitor changes in mitochondrial superoxide, isolated fibers from the AT muscle were loaded 
with MitoSOX Red (250nM, Invitrogen) for 30min as previously described (36). Fibers were maintained in 
buffer Z containing MitoSOX Red (20nM) during the experimental period. The reaction between superoxide 
and MitoSOX Red generates a specific red fluorescent product, 2-hydroxyethidium (2-OH-Mito-E+) (37), 
monitored at an excitation/emission wavelength of 405/605nm (see Fig. 2A). Measurement of mitochondrial 
membrane potential (ΔΨm) in intact mitochondria of isolated AT fibers was assessed by tetramethylrhodamine, 
methyl ester (TMRM, 30nM, Invitrogen) fluorescence at an excitation/emission wavelength of 543/605nm (see 
Fig. 6C). Changes in ΔΨm were determined in the presence of oxidative phosphorylation inhibitors; oligomycin 
(Olm, 2.5μM) and FCCP (4μM) as indicated in schematic Fig. 6C.  
 
Enzymatic activity assays. Enzymatic activity of CuZnSOD and MnSOD was assessed in native gels, with 
negative staining (see Fig. 2H), as described previously (6, 8). Aconitase activity was quantified by measuring 
the reduction of NADP+ to NADPH following addition of 2U of isocitrate dehydrogenase by using a microplate 
fluorometer (FLUOstar Optima, BMG) at an excitation/emission wavelength of 360/460nm (38). Mitochondrial 
enzyme citrate synthase (CS) activity was determined spectrophotometrically using the MitoCheck Citrate 
Synthase Activity Assay (Cayman Chemicals) according to manufacturer’s protocol. Respiratory chain complex 
I activity in skeletal muscle homogenates was examined by the reduction of 2,6-dichloroindophenol (DCIP), 
followed spectrophotometrically at 600nm as described by Janssen et al (39). 
 
Quantitative RT-PCR analysis. RNA from skeletal muscle was extracted, DNase-treated and purified using 
Direct-zol RNA miniprep (Zymo Research). Purified RNA was utilised to generate first-strand cDNA using the 
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iScript cDNA Synthesis kit (Bio-Rad). Primers for qRT-PCR analyses are shown in Table 1 and the optimal 
annealing temperature for each primer set was determined by using an annealing temperature gradient between 
55 and 62°C. Real-time PCR reactions were performed on an iCycler Detection System (Bio-Rad) using iQ 
SYBR Green Supermix (Bio-Rad). Specificity of the PCR products was determined by melt curve analysis and 
agarose gel electrophoresis. Three reference genes including GAPDH, beta-2-microglobulin (B2M) and 
ribosomal protein S29 (RPS29) were used as internal controls.  
 
Immunoblotting. Protein extracts (20µg/sample) were separated using a standard protocol for western blots 
(7). Peroxidase activity was detected using an ECL kit (Amersham International), and band intensities were 
analysed using Quantity One Software (Bio-Rad). Mitochondrial and cytosolic sub-cellular fractions were 
obtained from skeletal muscle as previously described (40).  
 
Statistical Analyses. Data are presented as mean ± SEM for each experiment. Statistical analyses for potential 
differences between groups were determined using analysis of variance (ANOVA) followed by the post hoc 
LSD test. Single comparisons between two experimental conditions were undertaken using the unpaired 
Student’s t test. Data were analysed using SPSS 22 and p values of less than 0.05 were considered statistically 
significant.  
 
 
Results  
Age-related loss of muscle mass is associated with myofiber atrophy. To determine the time-course of age-
related phenotypic changes that occur in skeletal muscle, we initially assessed anterior tibialis (AT) muscle 
mass at 12, 18, 24 and 28 months  of age in mice (Fig. 1A). AT muscle showed age-related loss of muscle mass 
(~34% reduction in mass relative to body weight) at 28 mo of age (Fig. 1A). To understand the structural 
muscle changes underlying sarcopenia, immunohistochemical analysis of AT muscle (Fig. 1B) was undertaken 
for 18 and 28 mo old mice. The total number of fibers/AT muscle tended to be reduced by a mean of ~11% in 
28 mo old mice in comparison with 18 mo old mice (Fig. 1C) but the changes were not significantly different. 
We then examined whether AT muscle of 28 mo old mice showed atrophy of the remaining muscle fibers (Fig. 
1D). Average muscle fiber cross-sectional area (CSA) was reduced significantly by a mean ~46% from 18 to 28 
mo of age suggesting that myofiber atrophy is the predominant cause of the loss of skeletal muscle mass that 
occurs between these ages.  
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Long-term administration of mitochondria-targeted antioxidant mitoquinone mesylate fails to attenuate 
age-related mtROS increase in muscle fibers from old mice. Previous studies from our group (16) and others 
(17) have shown that isolated skeletal muscle mitochondria exhibit an age-related increase in hydrogen peroxide 
(H2O2), which is associated with increased mitochondrial oxidative damage (21). To assess whether age-
dependent mtROS increase and oxidative damage are contributing factors to the loss of muscle mass that occurs 
with aging, 24 mo old mice were treated with mitochondria-targeted mitoquinone mesylate for 15 weeks. We 
chose to administer the compound between the ages of 24 to 28 mo old since our data (Fig. 1A) revealed that 
loss of muscle mass occurs post 24 mo of age. To assess the antioxidant effect of mitoquinone mesylate, single 
muscle fibers isolated from the AT muscle of control and mitoquinone mesylate-treated old mice were loaded 
with MitoSOX Red (Fig. 2A, top). Mitoquinone mesylate treatment was found to increase the 2-OH-Mito-E+ 
fluorescence (Fig. 2A, bottom) indicating a potential increase in mitochondrial superoxide productio. To further 
assess changes in mtROS, in the presence of mitochondrial substrates and inhibitors, we determined H2O2 
efflux from intact mitochondria in permeabilized myofibers from the AT muscle (Fig. 2B, C). Saponin-
permeabilized fibers from the AT muscle displayed good morphology and well-defined striations along the 
sarcolemma and stained positive for TO-PRO-1 iodide indicating plasma membrane permeabilization (Fig. 2B). 
Glutamate/malate (complex I substrates) and succinate (complex II substrate) fuelled mitochondria from treated 
old mice showed a tendency towards a higher increase in H2O2 emission compared with control old mice (Fig. 
2C), but did not reach statistical significance. The succinate induced H2O2 release was abolished by the complex 
I inhibitor, rotenone, suggesting that this H2O2 release likely derives from complex I (Fig. 2C). 
 
As these results were unexpected, we next sought to determine whether long-term administration of 
mitoquinone mesylate altered the expression of potential sources for mtROS generation including complex I, II, 
III (41) and mitochondrial nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4), (14, 36). To assess 
mitochondrial protein levels of NOX4, mitochondrial and cytosolic fractions from skeletal muscle of control 
and mitoquinone mesylate-treated old mice were prepared (Fig. 2E). We observed no changes in protein 
expression of complex I, II and III (Fig. 2D) or mtNOX4 (Fig. 2F). Similarly, no changes were observed in the 
enzymatic activities of respiratory complex I (Fig. 2G) or mitochondrial matrix superoxide dismutase 2 (SOD2) 
(Fig. 2H). A tendency to a reduction in SOD1 activity was observed in skeletal muscle of mitoquinone 
mesylate-treated old mice compared to control old mice, (p=0.06). These findings were somewhat surprising, 
but indicate that long-term mitoquinone mesylate treatment of old mice failed to attenuate the age-related 
increase in ROS generation by intact mitochondria in isolated skeletal muscle fibers. 
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Mitoquinone mesylate fails to attenuate oxidative damage in aging skeletal muscle. To determine if long-
term mitoquinone mesylate treatment altered levels of age-related oxidative damage in skeletal muscle (42-44), 
we next examined the amounts of protein oxidation, lipid peroxidation, DNA damage and protein nitration (Fig. 
3A-D). Mitoquinone mesylate treatment tended to increase age-related protein carbonylation (9) in whole AT 
muscle (Fig. 3A, top left), and mitochondrial fractions (Fig. 3A, top right). There was also a tendency for an 
increase in protein carbonyl content of cytosolic fractions from mitoquinone mesylate-treated mice (Fig. 3A, 
bottom). Assessment of lipid peroxidation in mitochondrial and cytosolic fractions from skeletal muscle of 
control and mitoquinone mesylate-treated old mice was undertaken by  immunoblotting for 4-hydroxynonenal 
(4-HNE) protein adducts (Fig. 3B). The data obtained were similar to those for protein oxidation in that 
mitoquinone mesylate-treatment tended to increase lipid peroxidation in both fractions (Fig. 3B). However, 
neither protein carbonylation nor lipid peroxidation markers showed statistically significant differences between 
control and mitoquinone mesylate-treated mice. The extent of oxidative DNA damage was also assessed by 
examining 8-hydroxydeoxyguanosine (8-OHdG) in genomic DNA and protein expression of oxoguanine DNA 
glycosylase (OGG1), a primary enzyme responsible for the excision of 7, 8-dihydro-8-oxoguanine lesion (45), 
(Fig. 3C). Muscle from mitoquinone mesylate-treated old mice showed a trend towards a reduction (p=0.09) in 
OGG1 protein levels (Fig. 3C, right/bottom), with no change in the levels of 8-OHdG (Fig. 3C, left). Finally, 
the level of protein nitration (3-NT) and the expression of peroxiredoxin V (PRXV), a peroxynitrite reductase 
(7), were determined (Fig. 3D), but no effects on 3-NT content (Fig. 3D, left) or PRXV expression (Fig. 3D, 
right/bottom) were observed. Overall, these data indicate that long-term administration of mitoquinone mesylate 
did not reduce oxidative damage in  muscle of old mice. 
 
Mitoquinone mesylate alters the expression of redox regulatory proteins in aging skeletal muscle. To 
determine whether long-term mitoquinone mesylate treatment of old mice caused adaptations in the expression 
of proteins involved in antioxidant defence, we measured the expression of redox regulatory proteins including; 
superoxide dismutase (SOD) isoforms (Fig. 4A), nitric oxide synthase (NOS) isoenzymes (Fig. 4B), H2O2 
scavenging enzymes including glutathione peroxidase 1 (GPX1), catalase (CAT) and PRXIII (Fig. 4C), redox 
proteins involved in the thioredoxin-peroxiredoxin (TRX-PRX) system (Fig. 4D) and heat shock proteins 
(HSPs), (Fig. 4E) which have all been shown to provide protection against the damaging effects of increased 
RONS production (6, 9). Densitometric quantification (Fig. 4F) of the blots presented in Fig. 4A-E revealed a 
significant reduction in protein expression of extracellular SOD3 isoform and mitochondrial SOD1. This was 
also associated with a trend towards increased levels of TRX-PRX regulatory proteins including thioredoxin 
reductase 1 (TRXR1), mitochondrial TRXR2, iNOS (the inducible isoform of NOS) and a reduction in HSC70 
(Fig. 4F). The NFκB signalling pathway is known to regulate the expression of iNOS (46) and ROS antioxidant 
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enzymes (4) and previous in vitro studies have demonstrated enhanced NFκB activation following incubation 
with mitoquinone mesylate  (47), we therefore examined activation of the NFκB pathway which we have 
previously shown to be increased in skeletal muscle of old mice (48). Muscle of mitoquinone mesylate-treated 
old mice showed no significant change in activation of the NFκB pathway as indicated by phosphorylation of 
IκB-α (Phospho IκB-α), total IκB-α content (a key inhibitor of NFκB activation) or NFκB-P65 protein content 
(total and phosphorylated), (Fig. 4G).  Overall, these data suggest that long-term treatment of mitoquinone 
mesylate may have altered the expression of a small number of specific redox regulatory proteins in skeletal 
muscle from old mice. 
 
Long-term mitoquinone mesylate treatment does not affect mitochondrial abundance in skeletal muscle 
of old mice. We sought to determine whether mitoquinone mesylate-treated old mice showed a change in 
mitochondrial abundance (15, 20), (Fig. 5A, B). Muscle of treated old mice showed a tendency to a reduction in 
mitochondrial DNA (mtDNA) copy numbers per nuclear genome (Fig. 5A) and citrate synthase activity (Fig. 
5B). Quantitative RT-PCR analysis of expression of genes involved in mitochondrial dynamics (fusion and 
fission) and biogenesis (Fig. 5C, top) showed that mRNA levels were similar between muscle of mitoquinone 
mesylate-treated and control old mice (Fig. 5C, bottom). Protein levels of the transcriptional coactivator and 
regulator of mitochondrial biogenesis, peroxisome proliferator-activated receptor α (PGC-1α) did not differ 
between control and mitoquinone mesylate-treated old mice (Fig. 5D). A potential effect on mitophagy was 
investigated using isolated mitochondrial fractions from skeletal muscle of control and mitoquinone mesylate-
treated old mice immunoblotted for PTEN-induced putative kinase 1 (PINK1), and ubiquitin ligase Parkin 
mitophagy markers (Fig. 5E). We observed increased recruitment of PINK1, but no significant difference in 
Parkin in isolated mitochondria from mitoquinone mesylate-treated old mice (Fig. 5E) compared with values 
from control old mice, suggesting an increased mitophagic response. Levels of Sirtuin 1 (Sirt1), (Fig. 5D), an 
important regulator of mitochondrial recycling through the process of autophagy (49) were unchanged in the 
treated mice. 
 
Long-term mitoquinone mesylate treatment does not influence the mitochondrial membrane potential in 
intact mitochondria of permeabilized muscle fibers in old mice. Cumulative oxidative damage has been 
proposed to induce age-associated reductions in mitochondrial function (24, 50), thus we investigated 
mitochondrial function in skeletal muscle of mitoquinone mesylate-treated old mice (Fig. 6A-E). Skeletal 
muscle of mitoquinone mesylate-treated old mice exhibited similar levels of mitochondrial aconitase activity 
(Fig. 6A) and mitochondrial protein levels (Fig. 6B, top right) compared with control old mice, although a 
tendency to a reduction in aconitase content (p=0.06) was observed in the cytosolic compartment of the AT 
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muscle (Fig. 6B, bottom left). The mitochondrial membrane potential (ΔΨm) of intact mitochondria in isolated 
AT muscle fibers was examined by changes in tetramethylrhodamine, methyl ester (TMRM) fluorescence (Fig. 
6C, top) following treatment with oligomycin and the protonophore, FCCP (Fig. 6C, middle). Statistical 
analysis of the area under the TMRM fluorescence trace did reveal differences between mitoquinone mesylate-
treated and control old mice (Fig. 6C, bottom). Next, we evaluated mitochondrial respiratory function in 
saponin-permeabilized fiber bundles following addition of glutamate/malate substrates and ADP. Myofibers 
from mitoquinone mesylate administered old mice showed a trend towards a reduction (p=0.17) in respiratory 
control index (RCI), (Fig. 6D, left) associated with a trend towards increased uncoupling protein 2 (UCP2) 
protein levels (p=0.06), (Fig. 6E). No changes in P:O ratio (Fig. 6D, right) or UCP3 protein expression (Fig. 6E) 
were observed in mitoquinone mesylate-treated old mice compared with control old mice.  
 
Mitochondrial-mediated apoptosis is not altered in response to long-term mitoquinone mesylate 
treatment in aging skeletal muscle. A variety of pro-apoptotic markers were examined including expression of 
BAK, BAX and VDAC1 (Fig. 7A), proteolytic enzymes linked to apoptosis including expression of calpain I 
and calpastatin (Fig. 7B), mitochondrial release of cytochrome c and Smac/DIABLO pro-apoptotic proteins to 
cytosol (Fig. 7C), mitochondrial endonuclease G (Fig. 7D) and DNA fragmentation of genomic DNA (gDNA), 
(Fig. 7E). These results showed no changes in mitochondrial-mediated apoptotic processes in response to 
mitoquinone mesylate treatment. 
 
Long-term administration of mitoquinone mesylate failed to prevent the loss of muscle mass and function 
that occurred with aging. We first examined whether long-term mitoquinone mesylate treatment affected 
muscle mass and structure in old mice. The trend lines depicted in Fig. 8A showed no changes in body weight 
(BW) during the 15-week treatment. The tissue weights of several skeletal muscles and organs did not differ 
significantly between control and mitoquinone mesylate-treated old mice (Table 2), although there was a trend 
towards reduced spleen mass (p=0.12) and increased kidney mass (p=0.1). To assess changes in muscle 
morphology, transverse sections of AT muscle from control and mitoquinone mesylate-treated old mice were 
double immunolabeled with WGA, to visualize extracellular matrix, and DAPI, to mark nuclei (Fig. 8B). 
Histological analysis revealed no changes in number of centrally-nucleated fibers (Fig. 8C, left), total number of 
fibers/AT muscle (Fig. 8C, right) or average muscle CSA (Fig. 8C, bottom) in response to the mitoquinone 
mesylate treatment. Quantitative analysis of individual fiber CSA showed no differences in myofiber size (Fig. 
8D) or fiber type distribution (Fig. 8E) of AT or gastrocnemius (GTN) skeletal muscles between control and 
mitoquinone mesylate-treated old mice. Next, we examined the effect of mitoquinone mesylate administration 
on age-related changes in muscle function (5, 17), (Fig. 8F-J). Functional measurements of extensor digitorum 
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longus (EDL) muscle force production in situ revealed no changes in maximum isometric specific force 
between control and mitoquinone mesylate-treated old mice (Fig. 8F). In situ measurements of the decline in 
force generation by EDL muscles during a series of repeated isometric contractions revealed a trend towards a 
greater decline in force in mitoquinone mesylate-treated mice compared with values from control old mice (Fig. 
8G), but the apparent greater decline in the mitoquinone mesylate treated mice (Fig. 8G) was not statistically 
different. Finally, to evaluate the force production at the single-fiber level, we recorded ex-vivo muscle force of 
single isolated skinned fibers (Fig. 8H) obtained from the AT muscle. This allowed us to examine the force 
generated by sarcomeric proteins independent of innervation, fiber number, ATP levels and calcium release 
(51). Neither specific force (Fig. 8I) nor the time to peak maximum tension (Fig. 8J) differed between the 
control and mitoquinone mesylate-treated old mice. Collectively, these data reveal that long-term mitoquinone 
mesylate treatment did not alter age-related muscle atrophy, or any of functional deficits associated with aging 
skeletal muscle. 
 
 
Discussion 
Considerable evidence has indicated that skeletal muscle decline with advancing age is associated with an 
increased oxidative status in redox-responsive proteins (52) and increased oxidative modifications of 
macromolecules including DNA, proteins and lipids (4). Altered mitochondrial redox homeostasis has been 
proposed to play-a key role in sarcopenia (19, 21, 53) and skeletal muscle mitochondria have been reported to 
exhibit an age-dependent increase in mtROS (16, 17). Aging of skeletal muscle is associated with mitochondrial 
dysfunction including reduced maximal ATP-generating capacity, impaired function of the mitochondrial 
permeability transition pore and reduced maximal respiratory capacity (21, 31). Although cumulative oxidative 
damage has been suggested to induce age-associated decline in mitochondrial function (24), the effect of 
mitochondrial dysfunction and mtROS as the underlying key regulators of the age-related atrophy process 
remains an area of active research (25, 26).  
 
Skeletal muscle produces ROS from a variety of subcellular sites (14) and studies assessing the potential role of 
mtROS as the underlying mechanism of mitochondrial dysfunction and muscle wasting have been restricted, in 
part, by a the lack of interventions to selectively target mtROS. In the current study we determined the time-
course of age-related phenotypic/structural changes that occur in skeletal muscle and assessed the contribution 
of mtROS by utilizing the mitochondria-targeted ubiquinone derivative mitoquinone mesylate, which may 
selectively protect mitochondria from oxidative damage.  
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Data indicate that age-related loss of muscle mass occurred post 24 mo of age in these C57Bl mice, and was 
attributed to a significant reduction in fiber CSA, when compared with 18 mo old mice. Our findings are in 
agreement with recent human studies, highlighting age-dependent fiber atrophy as a primary cause of loss of 
muscle mass with advancing age (22). 
 
Previous work from our group (16) and others (17) has shown that age-dependent loss of muscle mass and 
function is associated with increased mitochondrial H2O2 emission and oxidative damage (21), suggesting that 
changes in mitochondrial redox homeostasis towards an oxidized state may be a contributor to skeletal muscle 
aging. To directly assess the effect of age-related changes in the mitochondrial redox environment, we used a 
long-term drug intervention approach, with use of mitoquinone mesylate. This compound has been developed as 
a therapy for humans and has undergone phase I and II clinical trials (28) and it comprises a ubiquinone moiety 
covalently attached through an aliphatic ten-carbon chain to triphenylphosphonium (TPP+), a lipophilic cation 
that accumulates several-hundred fold within mitochondria (54, 55). Mitoquinone mesylate is absorbed/bound 
to the matrix-facing surface of the inner mitochondrial membrane (into the hydrophobic core of the 
phospholipid bilayer) (54), driven by the membrane potential and there it is thought to be continually recycled 
to the active ubiquinol antioxidant by complex II of the respiratory chain (28). 
 
We assessed the potential of mitoquinone mesylate to rescue myofiber atrophy observed between 24 to 28 mo 
of age and provide evidence that drug treatment failed to prevent the age-related reduction in fiber CSA. We 
then examined the effect of long-term administration of mitoquinone mesylate to attenuate age-dependent 
changes in mtROS and redox homeostasis. To our surprise, mitoquinone mesylate treatment did not reduce 
mtROS or provide clear antioxidant protective effects, and in contrast we observed an increase in MitoSOX 
oxidation in the treated mice. Recent in vitro studies using skeletal muscle C2C12 cells have also provided 
similar results, palmitate-induced ROS production was further increased in response to mitoquinone mesylate 
treatment (56). Thus, the lack of any substantial antioxidant effects in response to mitoquinone mesylate 
administration did not allow us to directly address the original question posed in the current study: if age-
dependent changes in mitochondrial redox homeostasis play a major role in age-related muscle atrophy.  
 
Skeletal muscle of mitoquinone mesylate-treated old mice showed some alterations in the expression levels and 
activity of RONS regulatory systems and elevated mitophagic potential. We further addressed if mitoquinone 
mesylate influenced age-related changes in mitochondrial function and muscle force. We found that long-term 
administration of mitoquinone mesylate did not significantly alter mitochondrial function or muscle function 
though there was a tendency to adversely affect mitochondrial respiration and the decline in force during a 
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series of repeated isometric contractions. It is noteworthy that neither of these analyses reached statistical 
significance. In relation to this, recent in vitro studies using state-of-the-art respirometer technology (Seahorse 
Bioscience) have reported decreased mitochondrial respiration (56) and respiratory uncoupling (57) in skeletal 
muscle C2C12 myoblasts and endothelial cells in response to mitochondria-targeted coenzyme Q analogs.  
 
The relative increase in mitoSOX oxidation indicating increased mtROS seen in response to long-term 
administration of mitoquinone mesylate in vivo may be related to the quinone group, which has previously been 
shown to participate in redox cycling (53, 58). Quinone-containing compounds may undergo one-electron 
reduction by flavin-containing enzymes to form semiquinone radicals, which in turn may rapidly react with O2 
to produce superoxide (59, 60). The work presented in this study indicated that mitochondrial superoxide 
production, assessed via changes in MitoSOX Red fluorescence, was increased in response to the drug-
treatment. Other in situ and in vitro studies have also provided evidence that mitoquinone mesylate can augment 
mtROS production by complex I (58, 61) and previous work using sub-mitochondrial particles and purified 
mitochondrial complex I also suggested that redox cycling of mitoquinone mesylate can occur at the two sites 
on complex I, proximal and distal to the rotenone-binding site (53). 
 
Potential pro-oxidant effects of mitoquinone mesylate in vivo may also potentially be explained by the 
localisation of its large hydrophilic core in the aqueous phase. Factors that favor superoxide production by 
ubiquinones are reduction to the ubiquinol and the extent to which they are present in the aqueous environment 
(28, 62). Deprotonation of ubiquinol, the reduced form of mitoquinone mesylate, in the aqueous phase could 
lead to an oxidation reaction of quinol, generating superoxide (53, 62). These potential mechanisms offer 
plausible explanations why the current study has indicated that long-term mitoquinone mesylate treatment 
enhanced mtROS production in skeletal muscle of old mice.  
 
Previous in vivo studies have subjected rodents to long-term administration of mitoquinone mesylate in WT 
C57BL/6 (28) as well as a transgenic mouse model of Alzheimer’s disease (27) and have showed either 
antioxidant-protective effects (27), or lack of changes in redox homeostasis (28) in brain, liver and cardiac 
tissue. Both of these studies used young mice, at 4-8 weeks of age and the responses of tissues to this compound 
may potentially change in old organisms. Alternatively, it is possible that the inherent differences in specific 
tissue redox potential may alter the efficacy of mitoquinone mesylate in protecting mitochondria from oxidative 
damage.  
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To our knowledge this is the first study to utilize a long-term mitoquinone mesylate pharmacological approach 
and examine the effect on skeletal muscle mitochondrial redox homeostasis, organelle integrity and function as 
well as age-related loss of muscle mass and function that occurs with aging. We show that mitoquinone 
mesylate failed to attenuate age-related oxidative damage or rescue the sarcopenic phenotype and functional 
deficits associated with aging of skeletal muscle. 
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Legends to figures 
Figure 1. Sarcopenia is associated with myofiber atrophy. A) Age-related changes in anterior tibialis (AT) 
muscle mass, normalized to body weight (BW). *P<0.05 compared with values from the other age-groups, n=6-
8 mice/group. B) Transverse section of an AT muscle from an 18 mo old mouse stained with wheat germ 
agglutinin (WGA, 5μg/ml, red), to visualize extracellular matrix, and assess total fiber numbers and cross-
sectional area (CSA) of individual fibers. Scale bar, 500μm. C) Number of muscle fibers in AT muscle from 18 
and 28 mo old mice. D) Average fiber CSA of individual fibers from AT muscle of 18 and 28 mo old mice. 
*P<0.05 compared with values from 18 mo old mice, n=6-8 mice/group.  
 
Figure 2. Effect of long-term mitoquinone mesylate (MitoQ) administration on mtROS in skeletal muscle 
of old mice. A) Representative images of a single fiber isolated from the AT muscle under bright field, 
fluorescent image following loading with MitoSOX Red (20nM, Cyan), and a merged image as indicated and 
analyzed by confocal microscopy. 60x original magnification. Scale bar, 25μm (top panel); Statistical analysis 
of the area under the mitochondrial 2-hydroxyethidium (2-OH-Mito-E+) fluorescence trace (AUC) over 60min 
for control old mice and mice treated with mitoquinone mesylate (Graphs labelled as MitoQ-treated for brevity 
throughout) for 15 weeks (from 24 to 28 mo of age), Arbitrary Units (A.U), (bottom panel). 2-OH-Mito-E+ 
fluorescence was normalized to CS activity. *P<0.05 compared with values from mitoquinone mesylate-treated 
old mice, n=12 fibers, 5-6 mice/group. B) Confocal images of a saponin-permeabilized fiber isolated from the 
AT muscle under bright field, fluorescent image following loading with TO-PRO-1 iodide (200nM, Green) and 
4’,6-diamidino-2-phenylindole (DAPI, 1μg/ml, blue), and a merged image as indicated and analyzed by 
fluorescence microscopy. 60x original magnification. Scale bar, 25μm. C) Mitochondrial hydrogen peroxide 
(H2O2) production (normalized per CS activity) assessed in permeabilized fiber bundles prepared from AT 
muscle of control and mitoquinone mesylate-treated old mice. Mitochondrial substrates and inhibitors; 
Glutamate and Malate (G/M, 5mM for both), Succinate (S, 10mM) and Rotenone (Rot, 1μM) were added as 
indicated in figure. n=5-6 mice/group. D) Protein levels of oxidative phosphorylation (OXPHOS) complexes (I, 
II, III and V) from AT muscle of control and mitoquinone mesylate-treated old mice. The intensity of the bands 
shown in the Ponceau S-stained gel (top panel) was equivalent to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and Vinculin protein levels (bottom panel) and were used as loading controls. E) Example western 
blot of GAPDH and voltage-dependent anion channel 3 (VDAC3) content to illustrate the purity of the 
extracted mitochondrial (Mito) and cytosolic (Cyto) skeletal muscle fractions. F) Protein levels of NOX4 in 
skeletal muscle mitochondrial fractions of control and mitoquinone mesylate-treated old mice. G) Rotenone-
sensitive respiratory chain complex I activity in AT skeletal muscle homogenates of control and mitoquinone 
mesylate-treated old mice. n=5-6 mice/group. H) Native gels stained for SOD1 and SOD2 enzyme activities in 
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AT skeletal muscle of control and mitoquinone mesylate-treated old mice (top panel) and densitometric 
quantification of the bands (bottom panel). Negative control (NC) included AT muscle lysate from Sod1 null 
mice.  
 
Figure 3. Markers of oxidative damage in skeletal muscle from mitoquinone mesylate (MitoQ) treated old 
mice. A) Western blot analysis and quantification (bottom right panel) of protein carbonyls in mitochondrial 
(top right panel) and cytosolic (bottom left panel) skeletal muscle fractions, and AT lysates (top left panel) of 
control and mitoquinone mesylate-treated old mice. B) Western blot analysis (left panel) and quantification 
(right panel) of 4-hydroxynonenal protein adducts (4-HNE) in mitochondrial (top left panel) and cytosolic 
skeletal muscle fractions (bottom left panel) of control and mitoquinone mesylate-treated old mice. C) Levels of 
8-hydroxydeoxyguanosine (8-OHdG) in genomic DNA extracted from skeletal muscle (top left panel), and 
oxoguanine DNA glycosylase (OGG1) protein levels (bottom panel) of skeletal muscle from control and 
mitoquinone mesylate-treated old mice and densitometric quantification of the blot (top right panel). n=5-6 
mice/group. D) 3-nitrotyrosine (3-NT) content (top left panel), and peroxiredoxin V (PRXV) protein levels 
(bottom panel) of skeletal muscle from control and mitoquinone mesylate-treated old mice and densitometric 
quantification of the blot (top right panel). n=5-6 mice/group.  
 
Figure 4. Effect of long-term mitoquinone mesylate (MitoQ) treatment on RONS regulatory protein 
expression in skeletal muscle of old mice. A) Representative western blots depicting superoxide dismutase 
(SOD) isoform expression in AT lysates and mitochondrial/cytosolic skeletal muscle fractions of control and 
mitoquinone mesylate-treated old mice. B) Protein expression levels of nitric oxide synthase (NOS) isoforms in 
AT lysates of control and mitoquinone mesylate-treated old mice. C) Western blots of the main H2O2 reducing 
enzymes including; catalase (CAT), glutathione peroxidase 1 (GPX1), and peroxiredoxin III (PRXIII) in AT 
lysates of control and mitoquinone mesylate-treated old mice. D) Protein expression of the main redox proteins 
involved in the thioredoxin-peroxiredoxin system including; thioredoxin 1 and 2 (TRX1 and TRX2), 
thioredoxin reductase 1 and 2 (TRXR1 and TRXR2) in AT lysates of control and mitoquinone mesylate-treated 
old mice. E) Western blots of heat shock proteins (HSPs) in AT lysates of control and mitoquinone mesylate-
treated old mice. F) Densitometric analysis of the represented western blots shown in figures (A-E). *P<0.05 
compared with values from old control mice. G) Effect of long-term mitoquinone mesylate treatment on total 
and phosphorylated IκB-α (Phospho IκB-α) and P65 content (total and phosphorylated), (bottom left panel), and 
densitometric quantification of the blots (right panel). Coomassie brilliant blue-stained gel (top left panel) 
served as a loading control, molecular weight marker (M).  
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Figure 5. Effect of long-term mitoquinone mesylate (MitoQ) administration on mitochondrial content 
and mitophagy in skeletal muscle of old mice. A) Quantitative RT-PCR measurement of mitochondrial DNA 
(mtDNA), normalized to the amount of nuclear DNA (nDNA) in skeletal muscle of control and mitoquinone 
mesylate-treated old mice. n=5-6 mice/group. B) Citrate synthase (CS) activity in skeletal muscle of control and 
mitoquinone mesylate-treated old mice. n=5-6 mice/group. C) Representative image of agarose gel 
electrophoresis of the RT-PCR amplification products of GAPDH, B2M, RPS29, COXI, COXIV, CS, MCIP1, 
TFAM, PGC1α, NRF1, OPA1, MNF1, MNF2, FIS1, and DRP1 transcripts (top panel). Lanes 1 and 17, 100bp 
DNA molecular weight marker. The PCR products correspond to the amplicon sizes shown in Table 1. Relative 
mRNA levels of genes involved in mitochondrial biogenesis and dynamics, analyzed by quantitative RT-PCR 
(bottom panel). mRNA levels were normalized against the housekeeping genes; GAPDH, B2M and RPS29. D) 
Protein expression of sirtuin 1 (Sirt1) and peroxisome proliferator-activated receptor gamma coactivator-1-
alpha (PGC-1α) mitochondrial biogenesis regulators (left panel) in AT skeletal muscle of control and 
mitoquinone mesylate-treated old mice and densitometric quantification of the blots (right panel). E) Western 
blots of isolated mitochondrial fractions from skeletal muscle of control and mitoquinone mesylate-treated old 
mice immunodetected for PTEN-induced putative kinase 1 (PINK1), and ubiquitin ligase Parkin, mitophagy 
markers (left panel), and densitometric quantification of the blots (right panel).  
 
Figure 6. Mitochondrial function in skeletal muscle of mitoquinone mesylate (MitoQ) treated old mice. A) 
Mitochondrial aconitase (ACONS) activity in AT skeletal muscle of 28 mo old control and mitoquinone 
mesylate-treated mice. n=5-6 mice/group. B) Western blot analysis and quantification (bottom right panel) of 
ACONS in mitochondrial (top right panel) and cytosolic (bottom left panel) skeletal muscle fractions, and AT 
lysates (top left panel) of control and mitoquinone mesylate-treated old mice. C) Confocal images of a single 
fiber isolated from the AT muscle under bright field, fluorescent image following loading with 
Tetramethylrhodamine, methyl ester (TMRM, 20nM, Red) and a merged image as indicated and analyzed by 
fluorescence microscopy. 60x original magnification. Scale bar, 30μm (top panel); Measurement of ΔΨm in 
intact mitochondria of isolated AT fibers from control and mitoquinone mesylate-treated old mice, assessed by 
changes in TMRM fluorescence in response to oligomycin (Olm, 2.5μM) and the protonophore 
carbonylcyanide-p-trifluoromethoxyphenyl hydrazone (FCCP, 4μM), added at the indicated time points (middle 
panel); Statistical analysis of the area under the TMRM fluorescence trace (AUC) for control and mitoquinone 
mesylate-treated old mice (bottom panel). n=10-12 fibers, 5-6 mice/group. D) Respiratory function of intact 
mitochondria in saponin-permeabilized myofibers from control and mitoquinone mesylate-treated old mice 
shown by changes in respiratory control index (RCI) (left panel), and the ratio of ATP amount to consumed O2 
during state 3 (P:O) ratio (right panel). n=5-6 mice/group. E) Uncoupling protein 2 and 3 (UCP2 and 3) protein 
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levels in skeletal muscle of control and mitoquinone mesylate-treated old mice (left panel) and densitometric 
quantification of the blots (right panel).  
 
Figure 7. Effect of long-term mitoquinone mesylate (MitoQ) treatment on mitochondrial-mediated 
apoptosis in skeletal muscle. A) Immunoblots of BAK, BAX and VDAC1 pro-apoptotic proteins in skeletal 
muscle of control and mitoquinone mesylate-treated old mice (left panel), and densitometric quantification of 
the blots (right panel). B) Protein expression levels of calpain I and calpastatin proteolytic enzymes in muscle of 
control and mitoquinone mesylate-treated old mice (left panel) and densitometric quantification of the blots 
(right panel). C) Western blots of isolated cytosolic fractions of control and mitoquinone mesylate-treated mice 
immunodetected for cytochrome c (Cyt C) and Smac/DIABLO mitochondrial pro-apoptotic proteins (left 
panel), and densitometric quantification of the blots (right panel). D) Protein levels of proapoptotic factor 
endonuclease G (Endo G) in skeletal muscle mitochondrial fractions of control and mitoquinone mesylate-
treated old mice (left panel) and densitometric quantification of the blot (right panel). E) DNA fragmentation of 
genomic DNA isolated from skeletal muscle of control and mitoquinone mesylate-treated old mice, analyzed by 
agarose-gel electrophoresis. Lanes 1 and 10, 1kb DNA molecular weight marker.  
 
Figure 8. Effect of long-term mitoquinone mesylate (MitoQ) treatment on age-related loss of muscle mass 
and function. A) Time course of the changes in mouse body weight (BW) during the 15-week of mito-targeted 
mitoquinone mesylate administration. Trend lines indicate no changes in BW during the treatment period, BW 
was monitored weekly. n=5-6 mice/group. B) Transverse sections of AT muscle from 28 mo old control and 
mitoquinone mesylate-treated mice obtained following the 15-week treatment period, and stained with WGA 
(5μg/ml, green), to visualize extracellular matrix, and DAPI (1μg/ml, blue), to mark nuclei. Scale bar, 400μm. 
C) Percentage of fibers showing centrally located nuclei in AT muscle of control and mitoquinone mesylate-
treated old mice (top left panel); total number of muscle fibers in AT muscle of control and mitoquinone 
mesylate-treated old mice (top right panel); mean CSA of individual fibers from AT muscle of control and 
mitoquinone mesylate-treated old mice (bottom panel). n=5-6 mice/group. D) Frequency distribution of fiber 
CSA of AT muscle from control and mitoquinone mesylate-treated old mice. n=5-6 mice/group. E) 
Representative western blots of the fast (MHC fast) and slow (MHC slow) MHC content in gastrocnemius 
(GTN, top panel) and AT muscle (bottom panel) of control and mitoquinone mesylate-treated old mice. F) 
Maximum isometric specific force measured in situ, normalized to total fiber CSA of extensor digitorum longus 
(EDL) muscle from control and mitoquinone mesylate-treated old mice. n=5-6 mice/group. G) In situ 
measurements of the drop in maximum isometric specific force of EDL muscle during a series of repeated 
isometric contractions (300ms, at 100Hz, every 5s), expressed as a percentage of the initial force. Lines 
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represent the average response of 5 muscles. n=5 mice/group. Although mitoquinone mesylate-treated old mice 
showed a tendency to a greater decline in isometric force production during the fatiguing protocol compared 
with controls, the data were are not statistically significantly. H) Image of a skinned myofiber isolated from an 
AT muscle of a 28 mo old mouse, attached to a force transducer and high-speed length controller. Scale bar, 
350μm. I) Ex vivo measurements of maximum fiber specific force normalized to fiber CSA of skinned 
myofibers isolated from the AT muscle of control and mitoquinone mesylate-treated old mice. n=25 fibers, 5 
mice/group. J) Ex vivo measurements of the time to peak maximum tension of skinned fibers isolated from the 
AT muscle of control and mitoquinone mesylate-treated old mice. n=25 fibers, 5 mice/group.  
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Tables 
Table 1. Sequences of the specific primers used for quantitative RT-PCR amplification. 
Primer Name                 Forward Primer                                    Reverse Primer                      Amplicon Size                            
       (ID)                              Sequence                                               Sequence                                      (bp)  
GAPDH CCGTAGACAAAATGGTGAAGG TCGTTGATGGCAACAATCTC 109         
B2M GGAGAATGGGAAGCCGAACA TCTCGATCCCAGTAGACGGT 249         
RPS29 ATGGGTCACCAGCAGCTCTA GTATTTGCGGATCAGACCGT 102  
COX I CACTAATAATCGGAGCCCCA TTCATCCTGTTCCTGCTCCT 129  
COX IV TGGGAGTGTTGTGAAGAGTGA GCAGTGAAGCCGATGAAGAAC 273  
CS CAAGATTGTGCCCAATATCCTC TTCATCTCCGTCATGCCATA  111   
MCIP1 CAGCGAAAGTGAGACCAGGG ACGGGGGTGGCATCTTCTAC 309  
TFAM GCTGATGGGTATGGAGAAG GAGCCGAATCATCCTTTGC  161 
PGC1α TTCCACCAAGAGCAAGTAT CGCTGTCCCATGAGGTATT  131  
NRF1 TTACTCTGCTGTGGCTGATGG CCTCTGATGCTTGCGTCGTCT 92  
OPA1 TCAGCAAAGCTTACATGCAGA TGCTTGGACTGGCTACATTTT 180  
MFN1 TGCCCTCTTGAGAGATGACC AGAGCCGCTCATTCACCTTA 182 
MFN2 GGGGCCTACATCCAAGAGAG CCTTGGACAGGTACCCTTTG  115 
FIS1 GCCTGGTTCGAAGCAAATAC CACGGCCAGGTAGAAGACAT 116 
DRP1 CTGACGCTTGTGGATTTACC CCCTTCCCATCAATACATCC  277 
ND1 CCTATCACCCTTGCCATCAT GAGGCTGTTGCTTGTGTGAC 194 
PECAM 1 ATGGAAAGCCTGCCATCATG TCCTTGTTGTTCAGCATCAC  235 
 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; B2M, beta-2 microglobulin; RPS29, ribosomal protein S29; COX 
I, cytochrome c oxidase subunit I; COX IV, cytochrome c oxidase subunit IV; CS, citrate synthase; MCIP1, modulatory 
calcineurin interacting protein-1; TFAM, mitochondrial transcription factor A; PGC1α, peroxisome proliferator-activated 
receptor α; NRF1, nuclear respiratory factor-1; OPA1, optic atrophy type-1; MFN1, mitofusin-1; MFN2, mitofusin-2; 
FIS1, mitochondrial fission-1 protein; DRP1, dynamin related protein-1; ND1, mitochondrial encoded NADH 
dehydrogenase-1; PECAM 1, platelet endothelial cell adhesion molecule-1. 
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Table 2. Comparison of tissue weights from control and mitoquinone mesylate-treated old mice.  
Tissue           Mitoquinone mesylate       Control 
BW (gr) 35.2 ± 1.4 33.6 ± 2.6   
AT (mg) 43.4 ± 3.4 40.4 ± 2.9  
EDL (mg) 10.1 ± 0.5 9.8 ± 0.3  
GTN (mg) 154.6 ± 9.9 139.3 ± 6.6  
SOL (mg) 9.8 ± 0.7 8.7 ± 0.4  
Liver (gr) 1.91 ± 0.16 1.8 ± 0.13  
Spleen (mg) 134 ± 21.1 273.3 ± 72.3  
Kidney (mg) 273.2 ± 25.9 226.1 ± 12.8  
Heart (mg) 211.4 ± 14 195.3 ± 14.5  
Lung (mg) 185.2 ± 2.5 175.3 ± 8.9  
Brain (mg) 488.8 ± 4.9 468.6 ± 8.9  
Values are presented as the mean ± SEM; n= 5-6 mice/group.  
 
 
 
 
 
 








